Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study by Brandon J. Essink, Craig Shapiro, Marie Grace Dawn Isidro, Paul Bradley, Antoinette Pragalos, Mark Bloch, Joel Santiaguel, Melchor Victor Frias, Spiros Miyakis, Margarida Alves de Mesquita, Stefano Berrè, Charlotte Servais, Natasha Waugh, Claudia Hoffmann, Emna Baba, Oliver Schönborn-Kellenberger, Olaf-Oliver Wolz, Sven D. Koch, Tapiwa Ganyani, Philippe Boutet, Philipp Mann, Stefan O. Mueller, Roshan Ramanathan, Martin Robert Gaudinski, Nicolas Vanhoutte

Get full text

Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or ade... by Lucie Heinzerling, Michael Fluck, Caroline Robert, Celeste Lebbe, Erika Richtig, Sven D Koch, Ulrike Gnad-Vogt, Tobias Seibel, Thomas Eigentler, Juan Martin-Liberal, Sebastian Ochsenreither, Peter Mohr, Patrick Terheyden, Carsten Weishaupt, Michael Erdmann, Lukas Koch, Ainara Soria, Igor Samoylenko, Jürgen Krauß, Peter Brossart, Franz Georg Bauernfeind, Marina Gonzalez, Peter Wengenmayer, Ioannis Thomas, Artem Poltoratskiy, Marina Sekacheva, Beate Schmitt-Bormann, Gianluca Quintini, Martin Falk, Paula Codó, Arjun Oberoi, Jana Hess, Yulia Semiletova, Casilda Llacer Perez, Oliver Schönborn-Kellenberger

Get full text